Biotech Startups

4DMedical develops analytical software that extracts detailed lung function data from standard X-ray and CT scans, enabling non-invasive diagnosis and tailored treatment of respiratory conditions. Its technology serves clinicians and healthcare providers, including VA hospitals treating veterans exposed to toxic substances and airborne hazards.

1 investor

65LAB accelerates drug discovery and therapeutic company formation by connecting academic research institutions, life science investors, and Evotec to develop novel medicines into commercial entities. The organization identifies promising therapeutic projects, provides funding up to USD 1.5 million, and mentoring to achieve preclinical proof-of-concept before potential spinout.

1 investor

83bar operates a Patient Activation Platform that locates, educates, and recruits screened, qualified, high-intent patients for clinical trials and study sites. The company serves organizations running clinical research with patient recruitment and engagement software.

1 investor

858 Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies that act on tumor dependencies in DNA damage response (DDR) pathways. Its lead program, ETX-19477, is an oral PARG inhibitor being studied in patients with advanced solid tumors.

1 investor

9Bio develops cancer therapies by combining structural biology, artificial intelligence, and protein engineering to create novel oncology treatments. The company focuses on conditionally active therapeutics for cancer patients.

1 investor

Aakha Bio develops multi-specific antibodies for solid tumors that block disease pathways and activate immune cells. The company targets cancer patients with limited treatment options using a platform approach that integrates multiple therapeutic mechanisms into single molecules.

1 investor

Abalos Therapeutics develops immunotherapy treatments using arenavirus-based approaches for cancer. The company serves cancer patients and is located in Germany, operating in the biotech sector.

1 investor

Abarceo Pharma is a pre-clinical stage biotech developing a small molecule platform targeting mitochondrial dysfunction via the VDAC1 protein, with an initial focus on treatments for Type 2 Diabetes. A spin-out of Lund University Diabetes Center, it also aims at related mitochondrial conditions such as cardiovascular disease and Alzheimer's disease.

1 investor

ABclonal develops and manufactures reagents for life science research, including recombinant rabbit monoclonal and polyclonal antibodies, recombinant proteins, molecular biology enzymes and kits, immunoassay ELISA kits, and NGS library preparation products. Its catalog using the proprietary SMab technology serves research institutions and labs in areas such as cell biology, immunology, and diagnostics.

1 investor

AbelZeta develops T cell immunotherapies, advancing pipeline drug candidates through early-stage and investigator-initiated clinical trials to treat cancer and immune and inflammatory (I&I) diseases. The company runs an in-house platform for cell therapy development and partners with global pharmaceutical firms for clinical development and commercialization.

1 investor

Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.

1 investor

Abfero Pharmaceuticals is a clinical-stage pharmaceutical company developing oral iron chelators that target iron as a therapeutic pathway for diseases of iron overload. Its lead brain-penetrant small molecule, SP-420, is aimed at conditions such as transfusional systemic iron overload and age-related macular degeneration.

1 investor

Abilita Therapeutics is a drug discovery company focused on membrane protein targets, using its EMP (Enabled Membrane Proteins) technology based on directed evolution to create stability- and expression-enhanced protein variants for discovering and optimizing drug candidates.

1 investor

Ability is a biotechnology company developing highly-selective, immune cell-modulating antibody therapeutics for patients with inflammatory diseases and cancer. Its AbiLeap discovery engine uses AI and a database of antibody sequences to generate fully-human monospecific and bispecific antibodies, with a lead program targeting inflammatory skin diseases and other candidates for solid tumors.

1 investor

Abingworth is a venture capital and private equity firm specializing in life sciences and healthcare investments across seed, development, and clinical co-development stages. The firm manages 15 dedicated funds and has invested in over 200 companies across the United States and Europe.

1 investor

AbInitio uses AI models to predict molecular properties, optimize bioprocess conditions, and recommend cell line and media selections for biopharmaceutical development. The company serves pharma and biotech teams to accelerate the path from drug candidate to commercial manufacturing scale.

1 investor

1 investor

ABio-X is a life sciences incubation platform that creates and invests in biotech and pharmaceutical companies developing innovative medicines and technologies. The platform provides capital, operational support, and access to experienced entrepreneurs and industry networks to accelerate drug development pipelines.

1 investor

Abiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.

1 investor

Abionic develops the abioSCOPE, a near-patient rapid diagnostic platform that uses nanofluidic immunoassay technology to deliver lab-quality results from a single drop of blood within minutes. The platform is designed for clinical settings including hospitals and laboratories to enable early detection of conditions such as sepsis.

1 investor

ABIONYX Pharma is a biotech company developing therapies for diseases with no effective or existing treatment, including rare conditions. Its focus areas include drugs for renal and ophthalmological diseases and HDL-based vectors for targeted drug delivery.

1 investor

Boston Scientific develops cardiac electrophysiology mapping and ablation systems used by physicians to treat atrial fibrillation and other arrhythmias, including high-density mapping, pulsed field ablation, and electrographic flow source identification. Its systems support procedures such as pulmonary vein isolation through real-time catheter visualization and advanced electrogram analysis.

1 investor

Able Sciences works on cell engineering to develop next-generation disease-fighting cells.

1 investor

Abliva develops treatments for primary mitochondrial disease, a rare orphan disease caused by impaired cellular energy metabolism in the mitochondria. The company focuses on pharmaceutical research and development to address an unmet medical need where no effective treatments currently exist.

1 investor